Enhanced Formulations of SN-38 with Poly(amino acid) Block Polymers for Cancer Treatment

This inventive concept relates to novel formulations and delivery systems of SN-38 with poly(amino acid) block polymers, designed to improve the efficacy, safety, and efficiency of cancer treatment.

The original patent disclosed formulations of SN-38 with poly(amino acid) copolymers, but these formulations have inherent limitations, such as limited biodegradability, non-specific targeting, and potential side effects. The new inventive concept addresses these limitations by introducing modified poly(amino acid) block copolymers with improved biodegradability, targeting moieties for enhanced tumor specificity, and novel solvent systems for improved stability.

The new claims introduce four key improvements: (1) a method for treating cancer using a composition with a modified poly(amino acid) block copolymer for improved biodegradability, (2) a system for delivering SN-38 with a poly(amino acid) block copolymer matrix designed for sustained release over at least 7 days, (3) a composition with a poly(amino acid) block copolymer conjugated to a targeting moiety for enhanced tumor specificity, and (4) a method for manufacturing a composition using a novel solvent system to improve stability. These improvements enable more efficient and targeted delivery of SN-38, reducing potential side effects and improving treatment outcomes.

The new claims introduce novel and non-obvious modifications to the original formulations, including the use of modified poly(amino acid) block copolymers, targeting moieties, and novel solvent systems. These modifications provide a significant improvement over the original patent, enabling more effective and efficient cancer treatment.

Alternative embodiments of the inventive concept could include the use of different poly(amino acid) block copolymer architectures, varying the ratio of SN-38 to poly(amino acid) block copolymer, or incorporating additional therapeutic agents into the formulation. These variations could provide further improvements in efficacy, safety, and efficiency.

The inventive concept has significant commercial potential in the oncology market, with potential applications in treating various types of cancer. The improved formulations and delivery systems could provide a competitive advantage in the market, offering improved treatment outcomes and reduced side effects.